We use cookies to provide you with a better experience. By clicking the Accept button, you are agreeing to our use of cookies in accordance with our Privacy Policy.
  • Patient Resources
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
    • Glossary
  • Professional Resources
    • Research Center Profiles
    • Industry Provider Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
  • About Us
  • Contact Us
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » EMA now accepting Safe-BioPharma digital signatures on eSubmissions

EMA now accepting Safe-BioPharma digital signatures on eSubmissions

September 6, 2013
CenterWatch Staff

Beginning this month, SAFE-BioPharma digital signatures will be accepted by the European Medicines Agency (EMA).  

Acceptance of digital signatures is in line with EMA’s strategy for a “future electronic only workflow” between itself and the pharmaceutical industry by eliminating the need and cost associated with printing, sending and archiving paper documents. Electronic only workflows involving regulatory submissions will require use of E.U.-qualified digital signatures such as those based on the SAFE-BioPharma standard.

The agency is starting with digital signature-enabled PDF forms for scientific advice, orphan medicines, and pediatric submissions. 

In a related announcement underscoring the agency’s strategy to increase electronic-document-only exchanges with industry, EMA said it “will start to use digital signatures systematically in outgoing documents that currently require a legally binding signature.”

“EMA’s acceptance and use of digital signatures sends an important message to biopharmaceutical companies, many of which have digital signing capability as part of their existing use of SAFE-BioPharma digital identity credentials,” said Mollie Shields Uehling, president and chief executive officer, SAFE-BioPharma Association.

The SAFE-BioPharma standard was established by the pharmaceutical industry with the participation of the EMA and FDA to create and maintain an interoperable digital identity and signature standard that allows secure, trusted exchanges and legally-binding digital signatures. SAFE-BioPharma member companies have conducted several pilots with the EMA demonstrating that the SAFE-BioPharma standard meets E.U. electronic signature requirements and that the EMA can recognize and validate SAFE-BioPharma compliant signatures.

The E.U. definition of digital signatures is consistent with SAFE-BioPharma digital signatures. Specifically, each signature is:

  • uniquely linked to the signatory
  • capable of identifying the signatory
  • created using data that the signatory can use under his/her sole control with a high level of confidence
  • linked to the signed document in such a way that subsequent change in the document is detectable.

The EMA requires digital signatures on submissions be issued from Certification Authorities (CAs) under the authority of the national agencies on the E.U. trusted list.

Europe Ethics/Regulatory

Upcoming Events

  • 16Dec

    Master the Regulatory Pathway for Cell & Gene Therapy Submissions: Strategies for Successful BLAs

Featured Products

  • Regenerative-medicine-steps-to-accelerate-development-pdf

    Regenerative Medicine: Steps to Accelerate Development — PDF

  • Clinical-trial-agreements-a-guide-to-key-words-and-phrases-pdf

    Clinical Trial Agreements: A Guide to Key Words and Phrases — PDF

Featured Stories

  • Ich_logo

    ICH Overhauls 22-Year-Old Clinical Studies Guideline

  • Survey_chart2019

    Sponsors, CROs Doing Better, Sites Say, But More Work Is Needed

  • China-360x240

    U.S. Tops List of Trial Startups With China Making Progress in Phase 1

  • Phoneapp-360x240

    Device Apps Present Unique Risks in Trials

New!

2019 Site Survey Reports

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing